An article was published in February that looked at the real world patient outcomes for myelofibrosis patients with anaemia who were treated with ruxolitinib.
Titled ‘Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival‘, the full article is free to access.
The article concludes “these findings highlight the substantial burden of anemia in JAK inhibitor–naive patients with myelofibrosis and the challenges associated with ruxolitinib treatment in these patients. Optimal treatment strategies may differ between patients with vs without anemia in real-world practice.”
This article is likely to be of interest to myelofibrosis patients.
